NEW YORK, March 30, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Eagle Pharmaceuticals Inc. ("Eagle" or "the Company") (NASDAQ: EGRX). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at firstname.lastname@example.org or 212-697-6484.
This investigation concerns whether Eagle and certain of its officers and/or directors have violated the Federal Securities Laws under the Securities Exchange Act of 1934 (the "Exchange Act").
On February 25, 2016, Eagle's CEO announced regarding its New Drug Application (NDA) for the company's anticoagulant drug KANGIO™, "We have been interacting with FDA and we are preparing for launch, everything seems to be on track for a March 19 approval, and we anticipate shipping in late Q1 or early Q2." Then on March 18, 2016, Eagle announced that it had received a Complete Response Letter from the FDA, that the FDA "cannot approve the application in its present form and requested additional information" concerning KANGIO™'s ingredients.
Following this news, Eagle stock dropped $10.18, or 18.96%, to close at $43.50 on March 18, 2016.
If you are aware of any facts relating to this investigation, or purchased shares of Eagle Pharmaceuticals, you can assist this investigation by visiting the firm's website: http://www.bgandg.com/#!egrx/yazzb. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-eagle-pharmaceuticals-inc-egrx-300243391.html
SOURCE Bronstein, Gewirtz & Grossman, LLC